Coagulation factor XIII variants with altered thrombin activation rates

Biological Chemistry

Volumn 390, Issue 12, 2009, Pages 1279-1283

  Andersen, Mette Dahl ^a   Kjalke, Marianne ^a   Bang, Susanne ^a   Lautrup Larsen, Inger ^a   Becker, Peter ^a   Andersen, Asser Sloth ^a   Olsen, Ole Hvilsted ^a   Stennicke, Henning R ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Enzyme activation; Factor XIII; Factor XIII activation peptide; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; THROMBIN;

ARTICLE; BLOOD CLOT; ENZYME ACTIVATION; ENZYME ANALYSIS; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ENZYME ACTIVATION; FACTOR XIII; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, QUATERNARY; THROMBIN;

EID: 72949121067     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2009.142     Document Type: Article

References (31)

1. Achyuthan, K.E. (1998). Characterization of the reciprocal binding sites on human alpha-thrombin and factor XIII A-chain. Mol. Cell. Biochem. 178, 289-297.
2. Andersen, A.S. and Diers, I. (2002). Producing heterologous nonbacterial polypeptides, by culturing yeast strain having polynucleotide encoding polypeptide, under transcriptional control of yeast citrate synthetase gene promoter and isolating the product (Må løv, Denmark: Novo Nordisk). Patent number W0200244388-A.
3. Arië ns, R.A.S., Philippou, H., Nagaswami, C., Weisel, J.W., Lane, D.A., and Grant, P.J. (2000). The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96, 988-995.
4. Arië ns, R.A., Lai, T.S., Weisel, J.W., Greenberg, C.S., and Grant, P.J. (2002). Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100, 743-754.
5. Balogh, I., Szoke, G., Karpati, L., Wartiovaara, U., Katona, E., Komaromi, I., Haramura, G., Pfliegler, G., Mikkola, H., and Muszbek, L. (2000). Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 96, 2479-2486.
6. Bransford, C., Cheema, H., Hogg, D., Meng, W., Odonnell, R., Robertson, E., and Topping, A. (2006). Purifying factor XIII from biological fluid, by fractionating biological fluid by anion exchange, and then fractions by hydrophobic interaction, immobilized metal affinity chromatography, anion exchange, and collecting purified factor. ZYMOGENETICS INC, Patent number W02006056575-A1.
7. de Lange, M., Andrew, T., Snieder, H., Ge, D., Futers, T.S., Standeven, K., Spector, T.D., Grant, P.J., and Ariens, R.A.S. (2006). Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus. Arterioscler. Thromb. Vasc. Biol. 26, 1914-1919.
8. Egel-Mitani, M., Andersen, A.S., Diers, I., Hach, M., Thim, L., Hastrup, S., and Vad, K. (2000). Yield improvement of heterologous peptides expressed in yps1-disrupted Saccharomyces cerevisiae strains. Enzyme Microb. Technol. 26, 671-677.
9. Goldenberg, N.A., Hathaway, W.E., Jacobson, L., and Manco-Johnson, M.J. (2005). A new global assay of coagulation and fibrinolysis. Thromb. Res. 116, 345-356.
10. Greenberg, C.S., Achyuthan, K.E., and Fenton, J.W.D. (1987). Factor XIIIa formation promoted by complexing of a-thrombin, fibrin, and plasma factor XIII. Blood 69, 867-871.
11. Harris, J.L., Backes, B.J., Leonetti, F., Mahrus, S., Ellman, J.A., and Craik, C.S. (2000). Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. USA 97, 7754-7759.
12. Hornyak, T.J., Bishop, P.D., and Shafer, J.A. (1989). aThrombincatalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIIIa activity. Biochemistry 28, 7326-7332.
13. Isetti, G. and Maurer, M.C. (2004). Probing thrombin's ability to accommodate a V34F substitution within the factor XIII activation peptide segment (28-41)*. J. Pept. Res. 63, 241-252.
14. Katona, E.E., Ajzner, E., Toth, K., Karpati, L., and Muszbek, L. (2001). Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J. Immunol. Methods 258, 127-135.
15. Kohler, H.P., Arië ns, R.A., Whitaker, P., and Grant, P.J. (1998). A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb. Haemost. 80, 704.
16. Lee, I.H., Chung, S.I., and Lee, S.Y. (2002). Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A. Exp. Mol. Med. 34, 385-390.
17. Lim, B.C.B., Arië ns, R.A.S., Carter, A.M.,Weisel, J.W., and Grant, P.J. (2003). Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361, 1424-1431.
18. Lisman, T., Adelmeijer, J., Nieuwenhuis, H.K., and de Groot, P.G. (2003). Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul. Fibrinol. 14, 557-562.
19. Lorand, L. (2005). Factor XIII and the clotting of fibrinogen: from basic research to medicine. J. Thromb. Haemost. 3, 1337-1348.
20. Martin, P.D., Robertson, W., Turk, D., Huber, R., Bode, W., and Edwards, B.F. (1992). The structure of residues 7-16 of the A a-chain of human fibrinogen bound to bovine thrombin at 2.3 Å resolution. J. Biol. Chem. 267, 7911-7920.
21. Muszbek, L., Yee, V.C., and Hevessy, Z. (1999). Blood coagulation factor XIII: structure and function. Thromb. Res. 94, 271-305.
22. Muszbek, L., Ariens, R.A., and Ichinose, A. (2007). Factor XIII: recommended terms and abbreviations. J. Thromb. Haemost. 5, 181-183.
23. Nair, D.G., Sunilkumar, P.N., and Sadasivan, C. (2008). Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin. J. Biomol. Struct. Dynam. 26, 387-394.
24. Sadasivan, C. and Yee, V.C. (2000). Interaction of the factor XIII activation peptide with a-thrombin. Crystal structure of its enzyme-substrate analog complex. J. Biol. Chem. 275, 36942-36948.
25. Schechter, I. and Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162.
26. Trumbo, T.A. and Maurer, M.C. (2000). Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J. Biol. Chem. 275, 20627-20631.
27. Trumbo, T.A. and Maurer, M.C. (2002). Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P9 and P4 positions in factor XIII activation. Biochemistry 41, 2859-2868.
28. Trumbo, T.A. and Maurer, M.C. (2003). V34I and V34A substitutions within the factor XIII activation peptide segment (28-41) affect interactions with the thrombin active site. Thromb. Haemost. 89, 647-653.
29. Vokó , Z., Bereczky, Z., Katona, E., Adá ny, R., and Muszbek, L. (2007). Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb. Haemost. 97, 458-463.
30. Wells, P.S., Anderson, J.L., Scarvelis, D.K., Doucette, S.P., and Gagnon, F. (2006). Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and metaanalysis. Am. J. Epidemiol. 164, 101-109.
31. Yee, V.C., Pedersen, L.C., Le-Trong, I., Bishop, P.D., Stenkamp, R.E., and Teller, D.C. (1994). Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc. Natl. Acad. Sci. USA 91, 7296-7300.